कंपनी का अवलोकन
Alector, Inc. operates as a clinical-stage biotechnology firm dedicated to developing therapeutic interventions designed to counteract the progression of neurodegeneration within the United States market. The company functions within the healthcare sector, specifically in the biotechnology industry, which focuses on the discovery and development of innovative medical treatments for complex neurological conditions. As of the latest data, Alector, Inc. holds a market capitalization of $264.87M and reports annual revenue of $21.05M, while employing a workforce of 103 individuals. These financial figures indicate that the company is a small-cap entity with a market valuation that is significantly higher than its current revenue base, reflecting the high-risk, high-reward nature typical of early-stage biotechnology firms where future potential often outweighs current earnings. The discrepancy between the substantial market cap and modest revenue suggests that investors are pricing in the potential value of its pipeline assets, such as the investigational monoclonal antibody Nivisnebart, rather than current operational profitability.
वित्तीय स्वास्थ्य
The company reports a trailing twelve-month revenue of $21.05M, yet it simultaneously records a net income loss of $-142,928,992 and an EBITDA of $-147,367,008. The substantial gap between the $21.05M revenue and the net income loss of over $142 million reveals an aggressive cost structure where research, development, and operational expenses far exceed current sales generation. Alector, Inc. maintains a cash position of $256.02M against total debt of $36.23M, resulting in a free cash flow of $-114,339,128. The negative free cash flow indicates that the company is currently burning cash to fund its clinical trials and operational overhead, which limits immediate financial flexibility but is common for clinical-stage companies awaiting milestone payments or regulatory approvals. All three margin metrics reflect this operational phase: the gross margin is 0.0%, the operating margin is -587.5%, and the profit margin is 0.0%. The deeply negative operating margin of -587.5% highlights that for every dollar of revenue, the company incurs significant operating costs before reaching profitability, a pattern typical of biotech firms in the pre-revenue or early-revenue stage. Regarding leverage, the debt-to-equity ratio stands at 118.22, while the current ratio is 3.83, indicating strong short-term liquidity relative to obligations. Despite the high debt-to-equity figure, the massive cash reserve relative to debt suggests a conservative balance sheet structure regarding solvency risk. Finally, the Return on Equity is -181.6% and the Return on Assets is -25.1%, metrics that reveal management is currently deploying capital in a manner that dilutes shareholder value in the short term while building long-term product pipelines.
मूल्यांकन आकलन
The valuation metrics for Alector, Inc. present a challenging picture due to its lack of earnings, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -2.72. The forward P/E of -2.72, compared to the unavailable trailing P/E, implies that the market is not valuing the stock based on current or projected earnings power, but rather on asset value and pipeline potential. The price-to-book ratio is 8.63, indicating that the market values the company at a significant premium over its net book value, which is a common characteristic for biotechnology firms with valuable intellectual property. Additionally, the price-to-sales ratio is 12.59, and the EV/EBITDA is -0.31, suggesting that traditional valuation multiples are not applicable due to negative earnings, yet the price-to-sales multiple remains high relative to the $21.05M revenue. The stock trades with a 52-week high of $3.40 and a 52-week low of $0.87, meaning the current price sits at a level that reflects significant volatility within this defined trading range. The beta value of 0.58 indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market swings despite its high beta relative to a risk-free rate. These alternative valuation metrics suggest that investors are focusing on non-financial performance indicators such as clinical trial progress rather than traditional profitability metrics.
Growth & Income
Alector, Inc. reports a year-over-year revenue growth of -88.5%, while earnings growth is N/A due to the lack of positive earnings. The absence of positive earnings growth means that earnings cannot be compared directly to revenue growth in a traditional sense, as the company is not generating profits to analyze the divergence between the two. As a non-dividend payer, the company does not distribute a dividend yield, which is N/A, nor does it maintain a payout ratio, listed as 0.0%. This lack of dividend distribution implies that the company retains all available cash, even during periods of significant cash burn, to reinvest into research, development, and clinical trials rather than returning capital to shareholders. Consequently, the overall growth and income profile for Alector, Inc. is characterized by negative revenue growth and a complete absence of income generation, relying entirely on external capital sources and internal cash reserves to sustain operations until potential commercialization milestones are achieved.